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Abstract
Objective
Next-generation sequencing (NGS) was applied in molecularly undiagnosed asymptomatic or
paucisymptomatic hyperCKemia to investigate whether this techniquemight allow detection of
the genetic basis of the condition.
Methods
Sixty-six patients with undiagnosed asymptomatic or paucisymptomatic hyperCKemia, referred
to tertiary neuromuscular centers over an approximately 2-year period, were analyzed using
a customized, targeted sequencing panel able to investigate the coding exons and ﬂanking
intronic regions of 78 genes associated with limb-girdle muscular dystrophies, rhabdomyolysis,
and metabolic and distal myopathies.
Results
A molecular diagnosis was reached in 33 cases, corresponding to a positive diagnostic yield of
50%. Variants of unknown signiﬁcance were found in 17 patients (26%), whereas 16 cases
(24%) remained molecularly undeﬁned. The major features of the diagnosed cases were mild
proximal muscle weakness (found in 27%) and myalgia (in 24%). Fourteen patients with
a molecular diagnosis andmild myopathic features onmuscle biopsy remained asymptomatic at
a 24-month follow-up.
Conclusions
This study of patients with undiagnosed hyperCKemia, highlighting the advantages of NGS
used as a ﬁrst-tier diagnostic approach in genetically heterogeneous conditions, illustrates the
ongoing evolution of molecular diagnosis in the ﬁeld of clinical neurology. Isolated hyper-
CKemia can be the sole feature alerting to a progressive muscular disorder requiring careful
surveillance.
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Creatine kinase (CK) levels can be mildly and transiently
increased as a result of muscle injury or exercise, even in
healthy individuals. Persistent elevation of serum CK (termed
hyperCKemia) is deﬁned, according to European Federation
of Neurological Societies (EFNS) guidelines (ean.org/
Guideline-Reference-Center.2699.0.html), as the presence of
serum CK values beyond 1.5 times the upper limit of normal
(ULN) in least 2 measurements,1 and it is a common reason
for referrals to specialized neuromuscular centers.
Increased serum CK can be present in the absence of obvious
clinical signs.2 In individuals with a normal neurologic ex-
amination, the condition is termed asymptomatic or isolated
hyperCKemia, and it can signal the presence of several un-
suspected metabolic, cardiac, rheumatic, or endocrine con-
ditions. When no underlying cause is found, it is referred to as
idiopathic hyperCKemia. The clinical management of idio-
pathic hyperCKemia is unclear; although clinically asymp-
tomatic, aﬀected patients are potentially susceptible to
malignant hyperthermia.3
In asymptomatic hyperCKemia, deﬁnition of the correct di-
agnosis may be time consuming, and success is not guaran-
teed. Next-generation sequencing (NGS) has recently been
proposed as a cost-eﬀective strategy for the molecular di-
agnosis of inherited neuromuscular disorders.4 The eﬀorts to
deﬁne the molecular etiology in hyperCKemia come from the
need to reﬁne follow-up avoiding unnecessary examinations
and to improve counseling in the family. We set out to explore
whether NGS might allow detection of the molecular basis of
hyperCKemia, addressing this question in a consecutive series
of adults and children recruited at 7 Italian tertiary neuro-
muscular centers over an approximately 2-year period.
Methods
Standard protocol approvals, registrations,
and patient consents
This study was approved by the Tuscany Regional Pediatric
Ethics committee. All the procedures complied with the
Helsinki Declaration of 1975. Genetic studies and muscle
biopsies were performed with written informed consent. All
participants (including parents or legal guardians in case of
minor patients) were provided pre- and post-test genetic
counseling as routine in our neurogenetic clinics.
Patients and study design
Over an approximately 2-year period (May 2016–August
2018), 66 patients presenting with hyperCKemia (meeting
the EFNS criteria) were consecutively referred to the neu-
rology, pediatric, or neuropediatric units of 7 Italian tertiary
neuromuscular centers for clinical and diagnostic purposes.
All 66 met the inclusion criteria for our study: (1) persistent
serum CK elevation at rest and (2) values higher than twice
the ULN on at least 2 occasions after refraining frommuscular
exercise for at least 72 hours before CK measurement. For
each patient, we collected clinical and laboratory data and the
results of familial segregation analyses and previous genetic
tests. MRI scans of thigh and calf muscles were performed in
26 patients, EMG in 26, and muscle biopsy in 57, in all cases
using routine clinical methods.5 Before this study, we had
performed multiplex ligation-dependent probe ampliﬁca-
tion analysis in all the patients to exclude multiexon rear-
rangements in the DMD gene and tested the levels of acid
alpha-glucosidase from dried blood spots6 to detect possible
undiagnosed late-onset Pompe disease. Patients with bor-
derline enzyme values or biallelic mutations in the GAA
gene were not included in this study. DNA samples were
analyzed at a single center.
None of the 66 individuals had a medical history of anesthesia-
related complications or a family history of cardiovascular
events. Any family history of neuromuscular disorders or mild
muscle complaints was carefully recorded. Occasional causes of
hyperCKemia, such as malignancies, drug and alcohol abuse,
rheumatic, thyroid, and parathyroid disorders, infections, and
hematologic diseases, were all excluded. All patients underwent
routine serum chemistry, including serum myoglobin mea-
surement. No participant was under statin treatment or taking
other drugs potentially capable of inducing hyperCKemia.
NGS workflow and sequencing analyses
We used the SureSelect technology (Agilent, Santa Clara,
CA) and SureDesign software (earray.chem.agilent.com/
suredesign/) to design amultiexon amplicon panel containing
a total of 78 genes known to be associated with limb-girdle
muscular dystrophies (LGMDs), rhabdomyolysis, and meta-
bolic and distal myopathies7; the panel spanned more than
259 Mbp, with gene coverage >99%. To analyze the data
obtained from our study, we used a routine bioinformatic
pipeline8 that adopts the Ingenuity Variant analysis suite
(Qiagen, apps.ingenuity.com). To assign pathogenicity, we
set up a precise Alissa (Agilent) pipeline using the following
criteria: a sequence quality score greater than 30, a read depth
greater than 30, and rare occurrence in publicly available
polymorphic data sets (with a minor allele frequency <0.01%
for autosomal dominant and <0.1% for autosomal recessive
genes) with less than 1 occurrence in homozygosity in
Glossary
CK = creatine kinase; EFNS = European Federation of Neurologic Societies; HPO = Human Phenotype Ontology; LGMD =
limb-girdle muscular dystrophy;NGS = next-generation sequencing;ULN = upper limit of normal; VUS = variants of unknown
signiﬁcance.
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gnomADv2.1 (gnomad.broadinstitute.org/; macarthurlab.
org/2018/10/17/gnomad-v2-1). As reported previously, we
determined predictably or probably deleterious scores using
an in silico pipeline using a set of 10 prediction software
packages.8 Putatively deleterious variants were validated by
PCR-based standard capillary Sanger sequencing, both in
patients and in relatives whose DNA was available for segre-
gation studies, also to determine inheritance and phases of
multiple gene variants and to establish whether variants had
occurred de novo. Segregation in aﬀected and unaﬀected
relatives made it possible to better deﬁne pathogenic variants
once we had identiﬁed those more likely to be disease
causative.
Routine morphology and immunoﬂuorescence analysis of
muscle proteins were performed on vastus lateralis biopsy
samples according to standard protocols.
Data availability
The data set used and analyzed during the current study is
available from the corresponding author on reasonable request.
Results
We evaluated 66 patients with hyperCKemia (44 men and
22 women, age range 5–73 years), referred over an ap-
proximately 2-year period to tertiary neuromuscular centers.
Most of the patients were Italian, adults (≥16 years), and ap-
parently sporadic cases. Although none of them had obvious
neuromuscular disorders, 16 had a positive family history of
muscle weakness or fatigue compatible with autosomal domi-
nant inheritance in 13 and a recessive pattern of inheritance in
3. Their mean age at onset (i.e., at the time of the ﬁrst docu-
mented evidence of hyperCKemia) was 26.7 ± 19.2 years, when
they had serum CK levels ranging from 300 to 103,000 UI/L
(normal <190 UI/L). Their disease duration ranged from 3
months to 30 years. Clinical examination revealed mild limb-
girdle muscle weakness (median Medical Research Council
scale score of 5 in upper girdle and 4+ in lower girdlemuscle) in
19 patients (ﬁgures 1–2). The distribution of the muscle
weakness in these symptomatic patients is presented in ﬁgure 2
using the Human Phenotype Ontology (HPO) ID codes and
nomenclature.9 Thirteen participants reported occasional ex-
ercise intolerance andmyalgia, but showed no clear evidence of
muscle weakness. Thirty-four patients remained completely
asymptomatic over a 2-year observational period (ﬁgure 1).
The patients’ serum CK levels at their latest neurologic ex-
amination ranged from 150 to 64,610 UI/L.
Cardiac examination, performed at some point during the
course of the clinical follow-up, was unremarkable in all the
patients except 4 whose ECG showed arrhythmias of un-
certain signiﬁcance. Pulmonary and functional respiratory
tests were within normal limits in all the patients and
remained so throughout the study.
Figure 1 Flowchart of patients’ enrollment and results of genetic testing
VUS = variants of unknown significance.
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EMG, performed on average 1 year after hyperCKemia onset,
showed myopathic changes in 17 patients. Few patients un-
derwent repeated neurophysiologic follow-up, and none of
these showed substantial modiﬁcations. Twenty-six patients
underwent muscle MRI scans at least once during the study,
and these scans were unremarkable in 17 and not informative
in the other 9. Fifty-seven patients underwent a skeletal
muscle biopsy. In 8 cases (14%), this showed clear dystrophic
changes, with fat and connective tissue replacement suggest-
ing a possible diagnosis of muscular dystrophy, whereas the
vast majority (38/57, 67%) showed only mild, nonspeciﬁc
myopathic changes, with normal muscle protein staining and
no abnormal metabolic features (ﬁgure 3 and supplementary
ﬁgure e-1, links.lww.com/NXG/A175). Muscle biopsy was
normal in 11 patients.
Through multigene targeted NGS analysis, we identiﬁed an
average of 50 rare variants in each patient. To facilitate our
“needle in a haystack” search, we used a stringent set of bio-
informatics ﬁlters, including eﬀects on the protein, scores for
predicting pathogenicity, allele frequencies in public and
internal databases, and annotation as disease-associated var-
iants with Alissa, a customizable pipeline tool.10 Presence of
the speciﬁc variant in the HumanGenomeMutationDatabase
(hgmd.cf.ac.uk) was not considered a mandatory criterion for
attributing pathogenic signiﬁcance. Bioinformatics data were
combined and critically reevaluated taking into consideration
clinical presentation with the relative HPO deﬁnition, age at
onset, and segregation studies in familial cases. Moreover, in
cases submitted to muscle biopsy, we integrated histologic
and immunoﬂuorescence features.
On the basis of these procedural steps and criteria, already
used by us in previous research,7 we assigned a conﬁrmatory
genetic diagnosis to 19 patients presenting pathogenic,
disease-associated (n = 13), or likely pathogenic (n = 6)
variants. We also identiﬁed 14 patients harboring changes
predicted to aﬀect function in genes corresponding to the
clinical suspicions in these cases, thereby increasing group of
individuals with a molecular diagnosis to 33 patients. We
conﬁrmed the molecular diagnosis using segregation analysis
or immunoﬂuorescence, or Western blotting on muscle
Figure 2 Clinical features of symptomatic patients presented using HPO ID codes and nomenclature
(A) Muscle weakness pattern frequencies
expressed as percentage rates. Clinical
phenotypes are indicated using the HPO ID
codes. HP:0003325 = limb-girdle muscle
weakness; HP:0008994 = proximal muscle
weakness in lower limbs; HP:0003749 =
pelvic girdle muscle weakness. (B) Fre-
quencies of clinical phenotypes associated
with hyperCKemia expressed as percent-
age rates. Clinical phenotypes are in-
dicated using HPO codes and
nomenclature. HPO = human phenotype
ontology.
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biopsies, or their combination. Detailed information on these
patients, including clinical characteristics, CK levels, muscle
biopsy, and gene mutations, is shown in tables 1 and 2, whereas
the genetic data are summarized in ﬁgure 4 and further detailed
in supplementary web data (tables e-1 to e-4, links.lww.com/
NXG/A176, links.lww.com/NXG/A177, links.lww.com/
NXG/A178, and links.lww.com/NXG/A179).
Of the aforementioned 33 patients, 9 showedmild limb-girdle
muscle weakness, 10 showed myalgia and/or occasional ex-
ercise intolerance, and 1 case rhabdomyolysis, whereas 14
were asymptomatic despite having muscle biopsies showing
low immunoﬂuorescence for speciﬁc proteins (Figure 1, ﬁg-
ure e-1, links.lww.com/NXG/A175). Immunoﬂuorescence
analysis was performed to corroborate loss-of-function var-
iants in 7 cases. With regard to the genetic analyses, patho-
genic variants in RYR1 were found in 11 patients, in ANO5 in
4. Four patients harbored pathogenic variants in genes
encoding sarcoglycans, whereas 3 inCAPN3 (ﬁgure 4). Serum
CK levels in the group of molecularly deﬁned patients ranged
from 600 to 67,490 UI/L, whereas muscle biopsy (performed
in 31/33 individuals) showed evidence of dystrophic pro-
cesses in 6 (ﬁgure 3, ﬁgure e-1), mild nonspeciﬁc muscle
changes in 21, and no noteworthy alterations in 4 patients.
Variants of unknown signiﬁcance (VUS) with a potential caus-
ative role were found in 17 additional patients (supplementary
table e-3, links.lww.com/NXG/A178). In these cases, either
there was only a partial correspondence with the clinical phe-
notype or we discovered a single truncating variant (or a known
disease-associated variant) in a recessive candidate gene. Most
VUS occurred in 3 genes, namely CAPN3, CPT2, and ANO5
(ﬁgure 1 and supplementary table e-3, links.lww.com/NXG/
A178). Although it is possible that the low number of genes in
our panel limited its informativeness on the patients’ genotypes,
it is also conceivable that in the VUS subgroup, the second allele
may carry a deep intronic change leading to a mRNA splicing
defect or large scale gene deletions/duplications, or a variation in
genomic regulatory regions not covered in our study. Our study
explored none of these possibilities.
Sixteen patients harbored molecular ﬁndings not compatible
with their phenotypes. Although we cannot exclude a possible
role for some of the variants detected in this subgroup, other
additional and undetected genetic changes could well be re-
sponsible for their phenotypes.
Discussion
Both the EFNS guidelines1 and the authors of a more recent
review article35 recommend conducting further investigations in
individuals with apparently idiopathic hyperCKemia if the CK
level is repeatedly more than 3 times higher than the ULN, EMG
reveals myopathic changes, and the patient is younger than 25
years. However, it is anticipated that advancing knowledge in the
Figure 3 Myopathologic changes in patients with limb-girdle muscle weakness (top row, A–C), myalgia, and exercise
intolerance (middle row, D–F) and in asymptomatic patients (bottom row, G–I)
(A and B) Hematoxylin and eosin (HE)
staining demonstrating marked vari-
ation in fiber size, several central nu-
clei, and increased connective tissue
staining in P4 and P16, respectively.
(C) HE staining showing several
degenerating fibers in P29. (D) HE
staining revealing slight variation in
fiber size and some central nuclei in
P3. (E) Gomori trichrome staining
showing some hypotrophic fibers and
increased internal nuclei in P28. (F)
NADH-TR staining showing moth-
eaten fibers in P33. (G) HE staining
demonstrating mild variation in fiber
size and a few central nuclei in P7. (H
and I) Gomori trichrome staining
showing slight variation in fiber size
and some internal nuclei in P19 and
P22, respectively. Magnification 200×.
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Table 1 Clinical and genetic features in 13 patients with pathogenic variants
ID
Sex/
age (y)
Serum CK
(UI/L) Clinical findings HPO ID code
Muscle
biopsy
Mutated
gene Mutation cDNA level Mutation protein level Inheritance Reference
P9 F/54 y 1,310 Asymptomatic NA NA ANO5b c.1733T>C/c.2295C>G p.Phe578Ser/p.Tyr765* AR [11]
P10 F/61 y 2000 Limb-girdle muscle weakness HP:0003325 Mild
myopathic
signs
CAPN3b c.633G>T/
c.1537insCCCCATCTCTCAG
p.Lys211Asn/
Met513Thrfs*68
AR [12]
P13 M/32 y 1800 Myalgia and exercise intolerance HP:0003326; HP:
0009020
Normal TCAPc c.33_35del/- p.Glu12del/- AD This work
P15 M/7 y 7,348 Asymptomatic NA NA CAPN3b c.549delA/c.2115+2T>A p.Thr184Argfs*35/splice
sitea
AR [13,14]
P16 M/14 y 2,800 Limb-girdle muscle weakness HP:0003325 Dystrophic
signs
SGCGc c.195+1G>A/c.195+1G>A Splice sitea/splice sitea AR This work
P22 F/48 y 2000 Asymptomatic NA Mild
myopathic
signs
ANO5b c.1356C>G/c.1356C>G p.Tyr452*/p.Tyr452* AR This work
P25 M/11 y 19,000 Exercise intolerance and pelvic girdle
muscle weakness
HP:0009020; HP:
0003749
Dystrophic
signs
DMDc c.151_153del p.Leu51del XL This work
P27 F/67 y 900 Pelvic girdle muscle weakness HP:0003749 Mild
myopathic
signs
PYGMc c.2262delA/c.406G>A p.Lys754Asnfs*49/
p.Gly136Ser
AR [14]
P28 F/32 y 4500 Exercise intolerance and myalgia HP:0009020; HP:
0003326
Mild
myopathic
signs
SGCAc c.739G>A/c.850C>T p.Val247Met/p.Arg284Cys AR [15, 16]
P29 F/6 y 16,340 Limb-girdle muscle weakness HP:0003325 Dystrophic
signs
SGCGc c.521delT/c.521delT p.Leu174Leufs*21/
p.Leu174Leufs*21
AR This work
P30 M/66 y 1800 Asymptomatic NA Mild
myopathic
signs
ANO5b c.629C>T/c.726dupT p.Ser210Leu/
p.Ser243Phefs*2
AR [17]
P32 M/53 y 780 Myalgia and exercise intolerance HP:0003326; HP:
0009020
Mild
myopathic
signs
PYGM/
CPT2b
PYGM: c.[148C>T]; CPT2:
c.[1348A>T]
PYGM:p.[Arg50*]; CPT2:
p.[Arg450*]
NA [18–20]
P33 M/18 2,937 Myalgia and exercise intolerance HP:0003326; HP:
0009020
Mild myopathic
signs
MYH7b c.3790delG/- p.Glu1264Argfs*34/- AD This work
Abbreviations: AD = autosomal dominant; AR = autosomal recessive; HPO = Human Phenotype Ontology; NA = not available; XL = X-linked.
a Predicting splice site loss and exon skipping (fruitfly.org/seq_tools/splice.html). Functional validation was derived by bimmunofluorescence/protein studies combined with predictive early protein truncation or cimmuno-
fluorescence studies only.
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Table 2 Clinical and genetic features in 20 patients with “likely” pathogenic variants
ID
Sex/
age
(y)
Serum
CK (UI/
L)
Clinical
findings
HPO ID
code
Muscle
biopsy
Mutated
gene
Mutation
cDNA level
Mutation
protein level Inheritance Reference
P1 M/
19 y
3,000 Asymptomatic NA Mild
myopathic
signs
RYR1 c.8888T>C/- p.Leu2963Pro/- AD [21]
P2 M/
56 y
800 Asymptomatic NA Mild
myopathic
signs
RYR1b c.7373G>A/- p.Arg2458His/- AD [22]
P3 M/
68 y
816 Exercise
intolerance
HP:
0009020
Mild
myopathic
signs
RYR1 c.1163C>T/- p.Ser388Leu/- NA This work
P4d M/
48 y
1,044 Limb-girdle
muscle
weakness
HP:
0003325
Dystrophic
signs
GMPPBb c.95C>T/
c.727C>T
p.Pro32Leu/
p.Arg243Trp
AR [8, 23]
P5 F/65
y
600 Myalgia HP:
0003326
Mild
myopathic
signs
MYH7 c.2009T>C/- p.Val670Ala/- NA This work
P6 M/
17 y
865 Asymptomatic NA Mild
myopathic
signs
RYR1b c.7291G>A/- p.Asp2431Asn/- NA [24]
P7 M/
32 y
1,000 Asymptomatic NA Mild
myopathic
signs
RYR1b c.5036G>A/- p.Arg1679His/- AD [25]
P8 M/
40 y
1,000 Myalgia HP:
0003326
Mild
myopathic
signs
RYR1b c.7048G>A/- p.Ala2350Thr/- AD [26]
P11d F/51
y
3,000 Limb-girdle
muscle
weakness
HP:
0003325
Dystrophic
signs
DYSFc c.862G>T/
c.2875C>T
p.Asp288Tyr/
p.Arg959Trp
AR [27]
P12 M/
11 y
728 Myalgia and
exercise
intolerance
HP:
0003326;
HP:
0009020
Mild
myopathic
signs
RYR1b c.6599C>T/- p.Ala2200Val/- AD [28]
P14 F/65
y
3,300 Limb-girdle
muscle
weakness
HP:
0003325
Dystrophic
signs
ANO5 c.580C>T/
c.2219C>T
p.Arg194Trp/
p.Ser740Phe
AR This work
P17d M/5
y
67,490 Rhabdomyolysis HP:
0003201
Mild
myopathic
signs
CPT2b c.338C>T/
c.338C>T
p.Ser113Leu/
p.Ser113Leu
AR [29]
P18 M/
29 y
600 Asymptomatic NA Normal RYR1b c.[4711A>G;
10097G>A]/
c.11798A > G
p.[(Ile1571Val;
Arg3366His)]/
p.Tyr3933Cys
NA [30–32]
P19 M/
39 y
2000 Asymptomatic NA Normal CAPN3 c.[1,395_
1397del;
2257G>A]/
1453A>G
p.[(Leu465_
Glu466del;
Asp753Asn)]/
p.Met485Val
AR [12, 32, 33]
P20d M/
24 y
12,000 Asymptomatic NA Mild
myopathic
signs
SGCA c.242G>A/
c.739G>A
p.Arg81His/
p.Val247Met
NA [15]
P21 F/53
y
500 Limb-girdle
muscle
weakness
HP:
0003325
Mild
myopathic
signs
RYR1 c.10923-
8C>A/-
Splice sitea/- NA This work
P23 M/
64 y
1,000 Asymptomatic NA Mild
myopathic
signs
RYR1 c.14812A>G/- p.Ile4938Val/- NA This work
P24d M/
67 y
1,103 Myalgia HP:
0003326
Mild
myopathic
signs
MYOT c.179C>T/- p.Ser60Phe/- AD [34]
Continued
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ﬁeld ofmuscle disorderswill lead to the identiﬁcation of previously
unrecognized causes of hyperCKemia, thereby reducing the pro-
portion of idiopathic cases. This would be an important de-
velopment, as it would allowmore precise clinical monitoring and
follow-up and help to clarify the natural history of the diﬀerent
forms.
Studies conducted before NGS entered the clinical arena consid-
ered the diagnostic impact of muscle biopsy in the evaluation of
patients with asymptomatic hyperCKemia2,3,36–38 and the relative
frequency of common genes such as DMD.38 In recent years,
NGS,which has involved the development of diﬀerent gene panels
and seen the focus switch to peculiar muscle phenotypes, has
transformed the approach to the study of neuromuscular disorders
(the relevant data are for the most part reviewed in reference 4).
Some studies have also addressed, among other aspects, the ge-
notype of patients with isolated hyperCKemia, reporting a limited
diagnostic yield (21%) in fewer than 40 patients.39,40
Herein, we report the results obtained in a cohort of 66
patients with hyperCKemia, half of whom were asymptomatic
on evaluation. Our use of massive parallel sequencing with
Figure 4 Diagnostic rates and molecular results
(A) Pathogenic or likely pathogenic variants were found in 50% of the patients, whereas 25.7% showed variants that required further characterization, and
24.3% did not present pathogenic variants. (B) Type of causative mutations identified in diagnosed patients: missense (67%), small indels (18%), splice site
variants (6%), and nonsense mutations (9%). (C) Bar chart showing number of patients with “pathogenic” (red), “likely pathogenic” variants (yellow), and
variants of unknown significance (green) for each gene.
Table 2 Clinical and genetic features in 20 patients with “likely” pathogenic variants (continued)
ID
Sex/
age
(y)
Serum
CK (UI/
L)
Clinical
findings
HPO ID
code
Muscle
biopsy
Mutated
gene
Mutation
cDNA level
Mutation
protein level Inheritance Reference
P26d M/
21 y
1929 Asymptomatic NA Normal POMT2c c.[1733G>A;
239C>T]/
c.707T>G
p.[(Arg578His;
Pro80Leu)]/
p.Leu236Arg
AR This work
P31 M/
26 y
40,000 Asymptomatic NA Mild
myopathic
signs
RYR1c c.5288C>T/
c.7681C>T
p.Pro1763Leu/
p.Leu2561Phe
NA This work
Abbreviations: AD = autosomal dominant; AR = autosomal recessive; HPO = human phenotype ontology; NA = not available.
aPredicting splice site loss and exon skipping (fruitfly.org/seq_tools/splice.html).
bFunctional validation derived by immunofluorescence/protein studies combined with predictive early protein truncation/previous published work with
evidences of pathogenicity.
cFunctional validation derived through immunofluorescence studies only.
d Patients with “likely” pathogenic variants confirmed by immunofluorescence analysis or previously published evidence of pathogenicity.
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a multigene panel combined with the application of stringent
bioinformaticsﬁlters, and integration ofmuscle phenotypes (both
clinical and morphological), produced a 50% diagnostic yield,
a rate higher than those previously reported.39,40 This diﬀerence is
likely related to the combination of genotype with integrated
clinico-morphological phenotype data in the present study, to its
more homogeneous population (mostly adults in our cohort as
opposed to themixed populations studied by others), to technical
improvements implicit in more recent gene panel technologies,
or to a combination of these factors. There were no straightfor-
ward diﬀerences between the solved and unsolved participants,
with clinical features and serum CK values being roughly the
same in the 2 subgroups. Our data conﬁrm that main challenges
in NGS data analysis are the clinical interpretation of molecular
ﬁndings and the distinction of causative mutations from the
plethora of not clinically signiﬁcant DNA variations. The low
frequency of variants, or their absence in reference polymorphic
databases, is recognized as a necessary but not suﬃcient criterion
to assign pathogenicity. Moreover, in silico predictions present
often unanticipated discordance between diﬀerent predicting
algorithms.4 All this make more complex to reach a ﬁnal mo-
lecular diagnosis. Considering our results overall, there emerge
several points worth underlining. First, of the 33 patients who
received a molecular diagnosis, 11 harbored mutations in RYR1,
and all of these presented normal muscle MRI scans and subtle
muscle involvement on skeletal muscle biopsy. Only 1 presented
episodes of rhabdomyolysis, 2 presented myalgia, and 1 showed
mild limb-girdle muscle weakness. Conversely, 7 patients were
fully asymptomatic with a normal clinical evaluation associated
with serum steady CK levels ranging from 500 to 1,000 UI/L.
Although we did not seek to further corroborate our genomic
ﬁndings by evaluating their functional impact on intracellular
calcium homeostasis through complex studies or by performing
immunoblotting with commercial antibodies, all the detected
RYR1 variants were rare ones, namely those inherited segregated
in familial cases with clinical manifestations, and all are likely to
perturb secondary ryanodine-1 receptor structure in protein
modeling (not shown). Overall, our data imply that mutations in
RYR1may be a common in hyperCKemia, even when CK levels
are <1,000 UI/L. Of interest, we observed that the RYR1 par-
ticipants presented pseudometabolic features more frequently
than patients harboring other genotypes but did not stand up as
a clinically diﬀerent subgroup. Second, we identiﬁed biallelic
mutations in ANO5 in 4 patients and mutations in SGCA in 2
adults with long-lasting hyperCKemia without muscle weakness.
These data support previous impressions suggesting that analysis
of known LGMD genes is justiﬁed even when isolated hyper-
CKemia or minimal muscle weakness is the sole clinical
manifestation.41,42 Third, we frequently observed mild, non-
speciﬁc muscle abnormalities consisting of variation in ﬁber size,
nuclear internalization, or these 2 features combined; these
alterationswere always unrelated to serumCK levels, age at onset,
clinical features, disease duration, and mutated gene. Neverthe-
less, muscle biopsy remains an important part of the diagnostic
process in hyperCKemia, as it can also fulﬁll a “functional” role
assisting in the clariﬁcation of uncertain cases. This is illustrated
by case P28 in our study where 2 changes in SGCA were
substantiated by reduced α-sarcoglycan labeling in skeletal muscle
(ﬁgure e-1, links.lww.com/NXG/A175, A-B). Fourth, 26% of the
patients were found to harbor VUS. Nonetheless, we frequently
identiﬁed single deleterious variants in CAPN3 and CPT2, 2
autosomal recessive genes where manifesting heterozygosity re-
portedly occurs.43–45 The existence, in hyperCKemia, of symp-
tomatic carriers, various degrees of clinical severity, and large
intrafamilial heterogeneity of the phenotype (ranging from
asymptomatic to fatal) could be explained by factors other than
the genotype. In the case of CPT2-related myopathy, for exam-
ple, one might consider diﬀerent degrees of exposure to
triggering/environmental factors (e.g., temperature, nutrition,
ﬁtness level) capable of increasing dependency on fat oxidation
and further impairing exercise performance.46 Taking these fac-
tors into consideration, as well as the possibility of synergistic
heterozygosity34 (as in our case P32) and digenic inheritance, it is
imperative to combine thorough expert clinical and myopatho-
logic evaluation with NGS as a prelude to a higher diagnostic rate
in patients with paucisymptomatic hyperCKemia. Finally, iso-
lated hyperCKemia can be the sole feature alerting to a pro-
gressive muscular disorder requiring careful surveillance and may
open new prospective in future therapeutic opportunities.
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